

BLUE CROSS BLUE SHIELD

Federal Employee Program

PRIOR AUTHORIZATION REQUEST FORM

Date of Request:	02/01/2026	Request ID:	PA2026615740
------------------	------------	-------------	--------------

SECTION 1: MEMBER INFORMATION

Member Last Name:	THOMPSON	First Name:	MARGARET	MI:	
Date of Birth:	1953-09-28	Gender:	■ Female ■ Male	Phone:	912-555-0345
Member ID:	FEP234567891	Group Number:	FEP-RETIREE-2024	Plan Type:	PPO
Address:	156 Magnolia Lane, Savannah, GA 31401				

SECTION 2: PRESCRIBER/FACILITY INFORMATION

Prescriber Name:	Dr. William Barnes, MD, FACP
Specialty:	Internal Medicine
Practice Name:	Savannah Internal Medicine Associates
NPI:	1678912345
Address:	4700 Waters Avenue, Suite 300, Savannah, GA 31404
Phone:	912-555-0200
Fax:	912-555-0201

SECTION 3: MEDICATION/SERVICE REQUESTED

Drug Name (Brand/Generic):	Ibrance (Palbociclib)
NDC / J-Code / HCPCS:	J8999
Strength / Dose:	125 mg once daily
Route of Administration:	Oral
Frequency:	21 days on, 7 days off (28-day cycle); Combination: With fulvestrant 500 mg IM monthly
Duration of Therapy:	12 months initial authorization
Quantity Requested:	21 capsules per 28-day cycle
Site of Service:	Outpatient — oral medication, specialty pharmacy
Requested Start Date:	2026-03-01

SECTION 4: DIAGNOSIS INFORMATION

	ICD-10 Code	Diagnosis Description
Primary	C50.911	Malignant neoplasm of unspecified site of right female breast
Secondary	C79.51	Secondary malignant neoplasm of bone

SECTION 5: PRIOR TREATMENT HISTORY / STEP THERAPY

Medication	Dose/Route	Start Date	End Date	Outcome
Letrozole	2.5 mg daily	2023-07-15	2026-01-30	Progressive Disease

SECTION 6: CLINICAL INFORMATION / MEDICAL NECESSITY

Margaret Thompson is a 72-year-old female — HR+/HER2- metastatic breast cancer progressing on first-line endocrine therapy, requesting palbociclib + fulvestrant

72-year-old postmenopausal Caucasian female with HR+/HER2- metastatic breast cancer. Originally diagnosed June 2023 with Stage IIA right breast invasive lobular carcinoma, treated with lumpectomy and adjuvant radiation. Started adjuvant letrozole July 2023. Developed bone metastases (L2, L4, right femoral neck) detected on routine follow-up CT scan January 2025 — disease recurrence on adjuvant endocrine therapy. Continued letrozole with addition of denosumab for bone metastases. Progressed on letrozole by January 2026 with new L4 lesion and rising tumor markers. Oncologist at Memorial Health (via telehealth consultation) recommended switching to fulvestrant + palbociclib. However, patient's primary prescription is being written by her long-time internist Dr. Barnes, as she declined regular...

Disease Activity: Stage: IV (metastatic) | **Ecog Performance Status:** 1 | **Disease Status:** progressive_on_endocrine_therapy

SECTION 7: PRESCRIBER ATTESTATION

I certify that the information provided on this form is accurate and complete to the best of my knowledge. I attest that the requested medication/service is medically necessary for this patient. I understand that payment of claims will be from Federal and/or State funds, and that any false claims, statements, or documents may be prosecuted under applicable Federal and State laws.

Prescriber Signature:	_____	Date Signed:	02/01/2026
Print Name:	DR. WILLIAM BARNES	NPI:	1678912345